Quantitative whole-body measurement of inflammothrombotic immunologic response disease using Fleming method for tissue and vascular differentiation and metabolism.
Authors
Affiliations (1)
Affiliations (1)
- FMTVDM Frontier, Pearland-Houston, Texas, USA.
Abstract
Precision theranostics in nuclear medicine requires reproducible, calibrated quantification of tissue perfusion, and metabolism. This study evaluates whether the Fleming method for tissue and vascular differentiation and metabolism (FMTVDM) can quantify inflammothrombotic immunologic response disease (ITIRD) as a unified biologic continuum across cardiovascular, oncologic, and infectious/inflammatory conditions. This is a secondary analysis of six independent, Institutional Review Board-approved cohorts (total N = 2127) encompassing coronary artery disease (n = 1001), myocardial perfusion kinetics (n = 330), breast tissue differentiation by absolute count activity (n = 260) and maximum count activity (n = 35), infectious/inflammatory disease (n = 501), and systemic ITIRD assessment. All imaging was performed using calibrated FMTVDM quantification with artificial intelligence iterative analysis. Statistical methods included paired t-tests, analysis of variance, multivariate analysis of variance, Spearman correlations, and Poisson regression with Bonferroni correction for multiplicity. Coronary anatomy demonstrated a continuous, nonbinary relationship with physiologic impairment (Spearman rho = -0.68, P < 0.001), with postintervention FMTVDM showing a mean increase of 14.2% (95% CI: 11.8-16.6%). Myocardial kinetics distinguished normal, ischemic, stunned, and hibernating states (analysis of variance F = 24.7, P < 0.001). Breast maximum count activity values differentiated normal tissue (142 ± 18), ductal carcinoma in situ (192 ± 24), and invasive carcinoma (402 ± 87; F = 38.2, P < 0.001) in a pilot cohort. Infectious disease FMTVDM values correlated with ferritin (rho = 0.72) and interleukin-6 (rho = 0.68; both P < 0.001), with tissue-level improvement preceding biomarker normalization by 4.2 ± 1.8 days. FMTVDM provides reproducible, calibrated quantification of perfusion and metabolism across organ systems. These findings provide evidence supporting ITIRD as a measurable biologic continuum. Prospective, multicenter validation studies are warranted to confirm these associations and to establish the role of FMTVDM in precision nuclear medicine.